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Abstract
Objective This study’s aim was to describe and evaluate
outcomes of medical strategies used for lower urinary tract
symptoms (LUTS) treatment in general practice and to
assess impact of LUTS on patients’ general health-related
quality of life (HRQoL).
Methods This cross-sectional observational study was
conducted by French general practitioners. Eligible patients
were males aged C50 years, diagnosed for at least one year
and currently treated for LUTS due to benign prostatic
hyperplasia (BPH). Several validated questionnaires were
documented by patients to assess severity of LUTS (IPSS),
speciﬁc quality of life (IPSS-Q8), impact of LUTS (BII),
LUTS evolution (VNS) and general HRQoL (EQ-5D).
Results Among 1,098 patients included, 82.7% were
treated with monotherapies and 17.3% with combinations.
Mean treatment duration was 5.2 ± 3.2 years, and 47.2%
of patients had at least one treatment modiﬁcation since
initiation. Patients reported diminished quality of life
(IPSS-Q8 C3) (42.3%), persisting symptoms (IPSS-score
C12) (35.5%), symptoms worsening (VNS-score B-1)
(18.8%) and high bother (BII-score C9) (2.6%). Globally,
52.8% had at least one of these unsatisfactory outcomes.
Regarding general HRQoL, mean EQ-5D utility signiﬁ-
cantly decreased with LUTS severity (mild: 0.90 ± 0.12;
moderate: 0.81 ± 0.21; and severe symptoms: 0.73 ±
0.25; P\0.001). As well, all ﬁve-dimensions of EQ-5D
weresigniﬁcantly altered in patientswithmoderate-to-severe
LUTS (\0.001), especially ‘Pain/Discomfort’ and ‘Anxiety/
Depression’. In multivariate analyses including age and
comorbidities, EQ-5D utility index remained negatively
associated with each additional unit in the IPSS-score.
Conclusions This study shows that around half of BPH
patients medically treated report unsatisfactory outcomes,
suggesting consequential unmet medical needs in general
practice. Also, moderate-to-severe LUTS signiﬁcantly
impact on general HRQoL.
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Introduction
Benign prostatic hyperplasia (BPH) and its lower urinary
tract symptoms (LUTS) and complications represent a
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those aged over 50 years. More than half of patients (57%)
reporting a history of prostatic treatment have mild LUTS,
while 34 and 9% of patients suffer from moderate-to-
severe symptoms, respectively [1].
Current BPH management guidelines include several
therapeutic strategies [2, 3]. Pharmacological treatment is
currently recommended for the treatment of men with
moderate-to-severe LUTS who prefer to avoid invasive
treatment. There are two principal classes of pharmaco-
logical therapies for LUTS caused by BPH: alpha1-selec-
tive adrenergic receptor antagonists (alpha-blockers) and
5-alpha-reductase inhibitors (5-ARIs). Additionally, herbal
medicines are also prescribed to treat LUTS, especially in
France and Spain [4].
The increasing recognition of the importance of
patient-reported outcomes in BPH diagnosis and man-
agement has led to the development of disease-speciﬁc
questionnaires (i.e., International Prostate Symptom
Score, IPSS; and BPH Impact Index, BII) [5]. Addition-
ally, guidelines state that the primary consideration in
making treatment decisions and disease assessments about
BPH with LUTS should be the health-related quality of
life (HRQOL) to measure interference with social activi-
ties and decreasing psychological well-being [2, 6].
Inadequate management of LUTS can trigger disease
progression and lead to several complications [7]. As a
consequence, patient treatment satisfaction and HRQOL
assessment seem to be essential criteria to ensure optimal
treatment outcomes [8, 9], particularly in French general
practice where around nine out of ten prescriptions for
LUTS are ﬁlled [10].
The main objectives of this observational study were to
describe and evaluate outcomes of current medical strate-
gies used for LUTS treatment in daily general practice and
to assess impact of LUTS on patients’ general health-
related quality of life (HRQoL).
Methods
Patients and study design
This observational cross-sectional study was carried out in
France between October 2009 and January 2010, with the
participation of general practitioners (GPs) belonging to
the Longitudinal Patient Database (LPD) observatory. This
is a computerized network of GPs who contribute
exhaustive anonymous data on patient consultations and
treatment to the centralized LPD. The LPD includes
records for[1.6 million patients, routinely collected and is
a reliable source of information in numerous previous
studies in several disease areas [11].
The following criteria were used to recruit patients: aged
50 years or over with a clinical diagnosis of BPH, treat-
ment with one of the following pharmacological classes or
their combinations: an alpha-blocker or a 5-alpha-reductase
inhibitor or a phytotherapy.
At the end of routine consultation, physicians ﬁlled out
extra-computerized questionnaires detailing the comor-
bidities, ongoing medications and examinations. At home,
the patient completed anonymous questionnaires.
Patient questionnaires
Four speciﬁc and one generic instrument were used to
assess treatment outcomes.
The IPSS questionnaire is a validated seven-item urinary
symptom scale (0–35) [12] to which was added an eighth
disease-speciﬁc quality of life question (IPSS-Q8) [3]. The
BII is a disease-speciﬁc four-item questionnaire (0–13) that
measures the overall impact of LUTS on the general well-
being of patients [5]. LUTS evolution was evaluated from
the patient’s perspective using a visual numeric scale
(VNS) which range from -5 (extreme worsening) to 5
(extreme improvement) in relation to a 12-month retro-
spective period.
The last questionnaire, the EuroQOL-ﬁve-dimensions
(EQ-5D) index, is a well-validated comprehensive tool
developed to determine general HRQOL and health states
utilities (0–1; i.e., death–perfect health). Each dimension
can be answered as no problem, some problem, or severe
problem. Utility was calculated using French value set
from EuroQOL [13].
Statistical analysis
Descriptive analyses were provided for all variables.
Overall group comparisons were done by ANOVA for
quantitative data, and the chi-square or Fisher’s exact test
for qualitative data. All tests were two-sided and consid-
ered signiﬁcant when P\0.05.
The following four unsatisfactory outcomes were pre-
identiﬁed and described in terms of patient proportion:
(i) IPSS-score C12: persistent symptoms representing a
trigger for inclusion in previous clinical trials [14–16], (ii)
IPSS-Q8 C3: considered as a threshold for a (new) treat-
ment [2], (iii) BII-score C9: level of high bother [17] and
(iv) VNS-score B-1: worsening symptoms.
Utility derived from EQ-5D-index was treated as a
quantitative variable. Three linear models of utility as the
dependent variable were performed with the following
three independent variables: IPSS-score (Model 1), LUTS
severity (Model 2) and unsatisfactory outcomes (Model 3).
The models were obtained with step-by-step backward
selection where each variable with a P-value less than 0.25
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regression analysis.
Results
Patients ﬂowchart
Overall, 247 physicians recruited patients during the study
period. In total, 1,901 eligible patients were identiﬁed and
1,098 of them were ﬁnally enrolled. Reasons of non-
inclusion were non-consent (n = 757) and mental/physical
impairment (n = 46). Out of all the patients enrolled, 718
returned assessable questionnaires whose data were entered
into the outcomes analyses. Demographics and character-
istics of enrolled patients were comparable with those of
the entire population of the LPD database (n = 15,137) in
terms of age distribution and frequent comorbidities.
Patients’ characteristics
The mean age of the 1,098 men was 71.7 ± 8.9 years
(median: 72 years; 50–101). A minority of patients was
ﬁrst diagnosed by urologists (12.4%), and the remaining
patients were diagnosed by their current general practi-
tioner (Table 1). To date, 4.4 and 6.1% of patients had a
former history of AUR and surgery, respectively. A
majority of patients had several comorbidities.
LUTS management
The mean follow-up since BPH diagnosis was 6.2 ±
5.1 years, and the mean patient’s age was 65.5 ± 8.6 years
at the time of diagnosis (median: 65 years; 34–97). To
date, the most frequently reported clinical assessments used
for BPH diagnosis were informal questioning and digital
rectal examination (Table 1). Only 11.7% of physicians
used speciﬁc LUTS scores in clinical practice and among
them, 9.6% stated using speciﬁcally the IPSS-score.
Although not indicated in that case, both abdominal or
transrectal ultrasonography and PSA measurement were
commonly used at BPH diagnosis.
The mean treatment duration was 5.2 ± 3.2 years. The
overview of medications prescribed is reported in Table 1.
The majority of physicians prescribed combination thera-
pies as second-line treatment of LUTS (94.8%). The main
reasons of prescription were the following: monotherapy
inefﬁciency (74.4%), LUTS severity (53.8%), preventive
measures aimed to avoid complications (23.1%) or inva-
sive treatment (29.5%).
The mean current treatment duration was 2.4 ± 2.5 years
(median: 1.8 years; range: 0–10.9) for monotherapies and
1.3 ± 1.5 years (median: 8 months; range: 0–10.5) for
combination therapies. Since their treatment initiation,
47.2% of patients received at least one treatment modiﬁ-
cation. In 69.3% of patients, these modiﬁcations were
referred either to a switch to another pharmacological class
or to a drug combination.
The mean IPSS-score was 10.3 ± 6.5 points (median: 9
points), while 52.1% and 9.8% of treated patients had
moderate and severe symptoms, respectively.
Treatment outcomes
The patient-outcome data issued from questionnaires
completed by 718 (65.4%) patients were analyzed globally
and for three groups of patients deﬁned by their treatment
history: 434 patients (60.4%) with stable treatment (i.e.,
without treatment modiﬁcation during last 12-month), 151
patients (21.0%) with recent initiation of treatment (treated
less than 12-month) and a third group of 133 patients
(18.5%), considered as being in the treatment failure,
received at least one treatment modiﬁcation during the last
12-month. Proportions of unsatisfactory outcomes signiﬁ-
cantly varied according to patient’s treatment history
(P\0.001) (Fig. 1).
Among the whole sample, 42.3, 35.5, 18.5 and 2.6% of
patients reported diminished quality of life (IPSS-Q8 C3),
persisting symptoms (IPSS-score C12), symptoms wors-
ening (VNS-score B-1) and high bother (BII-score C9),
respectively. More than half of patients (52.8%) had at
least one of those unsatisfactory outcomes.
General HRQOL
All ﬁve-dimensions of EQ-5D were signiﬁcantly different
between severity classes (\0.001). Patients with moderate–
severe symptoms especially reported some or extreme
problems in ‘Pain/Discomfort’ (66.1–79.7%) and ‘Anxiety/
Depression’ (45.8–53.8%) (Fig. 2).
The mean utility derived from EQ-5D-index results was
0.84 ± 0.19 and was signiﬁcantly different among severity
groups: 0.90 ± 0.12, 0.81 ± 0.21, 0.73 ± 0.25 (\0.001)
for mild, moderate and severe LUTS, respectively. To
determine properly the relationship between LUTS and
EQ-5D utility index, an additional approach based on
multivariate method was performed (Table 2). This inclu-
ded available variables known to have a potential impact
on general HRQOL, such as socio-demographics and
comorbidities. In Model 1, each incremental unit of IPSS-
score represented a signiﬁcant decrease in EQ-5D utility
index (-0.009 [-0.012; -0.007]). Taking patients with
mild LUTS as reference, Model 2 showed a signiﬁcant
negative impact on EQ-5D utility index for those patients
suffering from moderate (-0.096 [-0.127; -0.065])-to-
severe LUTS (-0.159 [-0.210; -0.107]). In Model 3,
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123patients presenting at least one unsatisfactory outcome had
an EQ-5D utility index signiﬁcantly altered compared to
others (-0.091 [-0.120;-0.063]).
Discussion
Despite medical treatment, this study’s results showed that
half (52.8%) of the BPH population still had unsatisfactory
outcomes. However, it is not clear whether this is due to the
limited therapeutic effect of the available drugs or to their
inappropriate use. IPSS-Q8 was the most frequently
affected aspect (42.3% of patients). Furthermore, signiﬁ-
cant differences in those unsatisfactory outcomes were
observed according to the treatment history. The highest
burden was observed in the ‘recent therapeutic failure’
group, where 69.2% of patients had at least one of the
described criteria.
Table 1 Patients’ characteristics
Overall patients
n = 1,098*
[50–60] years
n = 117
[61–70] years
n = 371
[71–80] years
n = 417
[80 years
n = 191
Diagnosed by
General practitioner 959 (87.6%) 108 (92.3%) 326 (88.1%) 358 (86.3%) 165 (86.4%)
Urologist 136 (12.4%) 9 (7.7%) 44 (11.9%) 57 (13.7%) 26 (13.6%)
Diagnosis mode
Questioning 886 (80.7%) 95 (81.2%) 295 (79.5%) 335 (80.3%) 160 (83.8%)
Digital rectal examination 722 (65.8%) 68 (58.1%) 237 (63.9%) 292 (70.0%) 124 (64.9%)
PSA 635 (57.8%) 71 (60.7%) 219 (59.0%) 242 (58.0%) 101 (52.9%)
Ultrasonography 614 (55.9%) 71 (60.7%) 212 (57.1%) 228 (54.7%) 101 (52.9%)
Creatininemy 69 (6.3%) 8 (6.8%) 29 (7.8%) 26 (6.2%) 5 (2.6%)
Urinanalysis 56 (5.1%) 8 (6.8%) 22 (5.9%) 16 (3.8%) 9 (4.7%)
Symptom score 40 (3.6%) 4 (3.4%) 15 (4.0%) 15 (3.6%) 6 (3.1%)
Dipstick urine analysis 11 (1.0%) 2 (1.7%) 3 (0.8%) 5 (1.2%) –
Disease duration
Mean in years ± SD 6.2 ± 5.1 3.3 ± 2.8 5.0 ± 3.7 6.8 ± 5.3 9.0 ± 6.4
B5 years 582 (53.0%) 92 (78.6%) 236 (63.6%) 193 (46.3%) 59 (30.9%)
[5 years 516 (47.0%) 25 (21.4%) 135 (36.4%) 224 (53.7%) 132 (69.1%)
BPH-associated comorbidities
Acute urinary retention 48 (4.4%) 4 (3.4%) 16 (4.3% 12 (2.9%) 15 (7.9%)
Hypertension 676 (61.6%) 58 (49.6%) 211 (56.9%) 278 (66.7%) 127 (66.5%)
Type-II diabetes 184 (16.8%) 21 (17.9%) 59 (15.9%) 76 (18.2%) 28 (14.7%)
Dyslipidemia 489 (44.5%) 49 (41.9%) 163 (43.9%) 200 (48.0%) 76 (39.8%)
Body mass index
Mean in Kg/m
2 ± SD 27.0 ± 3.9 27.2 ± 3.9 27.2 ± 4.0 27.1 ± 3.9 26.4 ± 3.5
Median 26.5 26.7 26.5 26.6 26.3
Current treatment duration
Mean duration in years ± SD 2.2 ± 2.4 1.7 ± 2.1 2.0 ± 2.2 2.0 ± 2.2 2.7 ± 2.8
Median 1.6 0.9 1.4 1.8 2.1
Treatment type
Monotherapies 908 (82.7%) 96 (82.1%) 310 (83.6%) 348 (83.5%) 152 (79.6%)
Alpha-blocker 528 (58.1%) 62 (64.6%) 177 (57.1%) 223 (64.1%) 65 (42.8%)
Plant extract 242 (26.7%) 26 (27.1%) 94 (30.3%) 78 (22.4%) 43 (28.3%)
5-alpha-reductase inhibitor 138 (15.2%) 8 (8.3%) 39 (12.6%) 47 (13.5%) 44 (28.9%)
Combinations 190 (17.3%) 21 (17.9%) 61 (16.4%) 69 (16.5%) 39 (20.4%)
Alpha-blocker ? plant extract 94 (49.7%) 11 (52.4%) 27 (44.3%) 39 (56.5%) 17 (44.7%)
Alpha-blocker ? 5-alpha-reductase inhibitor 84 (44.4%) 8 (38.1%) 32 (52.5%) 24 (34.8%) 20 (52.6%)
5-alpha-reductase inhibitor ? plant extract 11 (5.8%) 2 (9.5%) 2 (3.3%) 6 (8.7%) 1 (2.6%)
* Including two patients for whom data on age were missing
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needs of men with LUTS can now be met by general
practitioners in a primary care setting [18]. Indeed in our
study, patients were diagnosed by GPs and only a small
proportion of them (12.4%) by urologists. Diagnostic
approaches, mentioned in LUTS management and follow-
up, include several clinical assessments as ultrasonography,
digital rectal examination and PSA measurement. Guide-
lines for LUTS management recognize the importance of
the assessment of patient health outcomes using LUTS-
speciﬁc questionnaires [2, 19]. The results of our study
suggest that these tools were used only by a small number
of physicians who preferred the ‘usual’ informal ques-
tioning of patients.
Most patients were treated with monotherapy, frequently
with alpha-blockers (58.1%) but also with 5-ARIs in par-
ticular among elderly patients. Considering the long natural
history of BPH and a well-known correlation of LUTS
severity and age, this may be explained by a depletion
effect of alpha-blockers leading to a switch to 5-ARI.
Potential sexual side effects of 5-ARI may be also more
acceptable to older patients. The proportion of prescribed
combination therapies was not negligible (17.3%) and may
reveal the magnitude of unmet needs with monotherapies.
This rate appeared to be consistent with the one previously
reported among patients treated by urologists (22.0%) [20].
Differences in mechanisms of action provide additional
arguments to use combination therapies (i.e., rapid
improvement of symptoms with alpha-blockers and a sus-
tained relief of symptoms with 5-ARIs) [21]. As well, a
possible synergistic effect between these two pharmaco-
logical classes has been suggested in two randomized
clinical trials, the MTOPS study (ﬁnasteride–doxazosin)
[16] and the recent CombAT study (dutasteride–tamsulo-
sin). Although not evidence based, the combination of
phytotherapy and alpha-blockers was prescribed in nearly
half of cases. An additional prescription of alpha-blockers
to patients that were already treated with phytotherapy can
probably explain this. However, in consistency with clini-
cal guidelines, the combination of a-blockers and 5-ARI
was also widely used (44.4%). Initial treatment was mod-
iﬁed for 47.2% of patients also indicating unmet medical
needs.
The results of this study suggest that all dimensions of
patients’ HRQOL measured with EQ-5D signiﬁcantly
decreased with LUTS severity. However, two-dimensions
appeared particularly altered: ‘Pain/Discomfort’ and
‘Anxiety/Depression’, suggesting that LUTS profoundly
inﬂuences the general well-being of patients as shown in
previous works [21–28]. As a generic tool, EQ-5D-index
allows indirect comparisons with those in other common
chronic diseases. For example, in our study, patients with
moderate and severe LUTS reported EQ-5D utility index
scores similar to patients suffering from chronic obstruc-
tive pulmonary disease (0.76 ± 0.21) [26], type-II diabetes
(0.79 ± 0.22) [27] or urinary incontinence (0.79 ± 0.22)
[28]. An important strength of this HRQOL analysis was its
attention to the effects of potential confounders. Although
patients with higher symptoms severity were older and
more likely to have comorbidities, IPSS-score (Model 1),
classes of severity (Model 2) and presence of unsatisfactory
outcomes (Model 3) were still signiﬁcant independent
determinants of general HRQOL. These data clearly indi-
cate that the negative impact of LUTS on HRQOL does not
appear to be related to other factors such as comorbidities
linked to age of patients.
Several limitations should be considered when inter-
preting the results of our study. Participating GPs were
ﬁrstly selected at random, but, since participation was vol-
untary, it is possible that participants may differ from GPs
who declined to participate and, as a consequence, leading
to a less representative sample. However, the strength of our
study was the availability of the LPD database which
allowed comparison of included and non-included patients
on several characteristics. The study population was also
shown to represent the entire disease population on several
characteristics (e.g., age and comorbidities).
Our ﬁndings provide evidence that unmet medical needs
remain high for a large proportion of patients in general
practice where many of them continue to receive mono-
therapy or even aberrant combined treatment. The patient
outcomes should be regularly reassessed during their fol-
low-up and considered more carefully at the treatment
decision making. As only a limited number of GPs fol-
lowed scientiﬁc clinical directives, developments of
advanced guidelines and effective strategies with GPs to
optimize BPH medical management and to persuade men
with LUTS to present earlier are required to improve
patient outcomes.
Fig. 1 Outcomes according to treatment history
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123Fig. 2 EQ-5D results by dimension and according to IPSS severity classes: mild (1–7), moderate (8–19) and severe (20–35)
Table 2 Variables signiﬁcantly associated with general quality of life (EQ-5D utility index scores): results of three multivariate linear
regressions
Dependent variable: utility* Model 1 Model 2 Model 3
Predicting variables Coefﬁcient
estimation

IC 95% Coefﬁcient
estimation

IC 95% Coefﬁcient
estimation

IC 95%
Intercept 1.096 [0.942; 1.250] 1.349 [1.227; 1.470] 1.315 [1.195; 1.434]
IPSS-score (for one unit increment) -0.009 [-0.012; -0.007] _ _ _ _
LUTS severity (mild symptoms as reference)
Moderate symptoms _ _ -0.096 [-0.127; -0.065] _ _
Severe symptoms _ _ -0.159 [- 0.210; -0.107] _ _
LUTS treatment unsatisafactory
outcome (at least one vs. none)
__ _ _ -0.091 [- 0.120; -0.063]
Others signiﬁcant variables
}
Age (for one-year increment) -0.006 [-0.007; -0.004] -0.006 [-0.007; -0.004] -0.006 [-0.007; -0.004]
Neuropsychiatric disorders (yes vs.
no)
-0.097 [-0.139; -0.055] -0.097 [-0.139; -0.054] -0.093 [-0.135; -0.052]
Cardiovascular risk factors (yes vs.
no)
-0.035 [-0.067; -0.003] -0.032 [-0.064; -0.001] -0.038 [-0.069; -0.006]
Joint diseases (yes vs. no) NS NS -0.036 [-0.072; -0.001] -0.037 [-0.072; -0.003]
* Utility reﬂects preference-based health-related quality of life derived from standardized instruments (i.e., EQ-5D) and which values range, by
convention, from 1.0 (perfect health) to 0.0 (death)
 Coefﬁcients represent changes in utility signiﬁcantly associated with the following health conditions: presenting one additional unit in IPSS-
score (Model 1), moderate or severe symptoms compared with mild symptoms (Model 2) and at least one unsatisfactory outcome compared with
none (Model 3)
} Other variables with a P value less than 0.25 in univariate analyses but not retained in ﬁnal multivariate analyses were pulmonary diseases,
gastro-intestinal disorders, renal insufﬁciency, back pain and education
NS not signiﬁcant
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